Evaluating low molecular weight heparins within a health system: Issues and strategies

Formulary

Volumn 34, Issue 2, 1999, Pages 144-148

  Armstrong, E P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; CLINICAL RESEARCH; DEEP VEIN THROMBOSIS; DRUG COST; DRUG SCREENING; HEALTH CARE; HUMAN; METHODOLOGY; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032974339     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Menzin J, Richner R, Huse D, et al. Prevention of deep-vein thrombosis following total hip replacement surgery with enoxaparin versus unfractionated heparin: A pharmacoeconomic evaluation. Ann Pharmacother 1994;28:271-5.
2. Colwell CW Jr, Spiro TE, Trowbridge AA, et al. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Clin Orthop 1995;321:19-27.
3. Planes A, Vochelle N, Darmon JY, et al. Risk of deep-vein thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-8.
4. Samama CM, Gigou F, Ill P. Low-molecular-weight heparin vs. unfractionated heparin in femorodistal reconstructive surgery: A multicenter open randomized study. Ann Vasc Surg 1995;9(Suppl):S45-53.
5. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-7.
6. Hull RD, Raskob GE, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med 1997;157:289-94.
7. Groce JB III. Patient outcomes and cost analysis associated with an outpatient deep venous thrombosis treatment program. Pharmacotherapy 1998;18(6 Pt 3):175S-80.
8. Thompson-Ford JK. Low-molecular-weight heparin for the treatment of deep vein thrombosis. Pharmacotherapy 1998; 18:748-58.
9. Martineau P, Tawil N. Low-molecular-weight heparins in the treatment of deep-vein thrombosis. Ann Pharmacother 1998;32:588-98,601.
10. Spinier SA, Nawarskas JJ. Low-molecular-weight heparins for acute coronary syndromes. Ann Pharmacother 1998;32:103-10.
11. Trujillo TC, Nolan PE. Unfractionated heparin in acute coronary syndromes: Has its time come and gone? Am J Health-Syst Pharm 1998;55:2402-9.
12. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-81.
13. Dedden P, Chang B, Nagel D. Pharmacy-managed program for home treatment of deep vein thrombosis with enoxaparin. Am J Health-Syst Pharm 1997;54:1968-72.
14. Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994;81:1742-6.
15. Hawkins DW, Langley PC, Krueger KP. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement. Am J Health-Syst Pharm 1997;54:1185-90.
16. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med 1997; 157:298-303.
17. Wade WE. Cost analysis of ardeparin versus enoxaparin for the prophylaxis of deep vein thrombosis after knee arthroplasty. Clin Ther 1998;20:347-51.
18. Devlin JW, Petitta A, Shepard AD, Obeid FN. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma. Pharmacotherapy 1998;18:1335-42.
19. Hulley S, Cummings SR. Designing Clinical Research. Baltimore: Williams & Wilkins; 1988.